Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC

•Who could obtain clinical benefit from EGFR/VEGF dual inhibition remains unclear?•We performed a meta-analysis using the data from 7 Phase II/III RCTs.•EGFR/VEGF dual inhibition led to favorable PFS among smokers than non-smokers.•Smoking status could predict the efficacy of EGFR-TKI plus anti-angiogenic agents.•No significant OS advantage was observed in both smoker and non-smoker subgroup.